Skip to main navigation
Syndax Pharmaceuticals, Inc. logo
  • About Us
    • About Us
    • Leadership
    • Board of Directors
    • Patient Community
  • Focus Areas
    • Focus Areas
    • KMT2Ar Acute Leukemias
    • NPM1m Acute Myeloid Leukemia
    • Chronic Graft-Versus-Host Disease
  • Pipeline
    • Pipeline
    • Menin Inhibitor
    • Anti-CSF-1R Monoclonal Antibody
    • Entinostat
    • Publications & Meeting Presentations
  • Our Products
  • Patients
    • Patients
    • Managed Access Programs
  • Investors
  • Careers
  • News
  • Contact Us

Press Release Details

Investors
  • Home
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Financial Overview
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
    • Analyst Consensus
  • Shareholder Services
    • Investor FAQs
    • Contact Us
    • RSS Feeds
    • Email Alerts

Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011

November 2, 2011
Pharmacodynamic-Data-from-Syndax-Pharmaceuticals-ENCORE-301-Study-in-Advanced-Breast-Cancer.pdf 433.4 KB
Syndax Pharmaceuticals, Inc. logo
  • About Us
  • Focus Areas
  • Pipeline
  • Our Products
  • Patients
  • Investors
  • Careers
  • News
  • Contact Us
Privacy Notice
Cookie Notice
Consumer Health Data Supplemental Privacy Notice
State Regulations
Terms of Use
Limit the Use of My Personal Information
© 2026 Syndax Pharmaceuticals, Inc.
linkedin x.com glassdoor